Searchable abstracts of presentations at key conferences in endocrinology

ea0063p923 | Diabetes, Obesity and Metabolism 3 | ECE2019

Flash glucose monitoring system in children under 18 years old with diabetes mellitus type 1 in the southern hospital area of Granada: preliminary results

Utrero Sara Leon , Ponce Maria Hayon , Laguna Ma Del Carmen Serrano , Torres Elena Lopez-Mezquita , Charneco Miguel Quesada , Vela Elena Torres

Objective: To evaluate the baseline characteristics and their evolution three months after implantation of the Flash glucose monitoring System (Freestyle Libre), after financing by the Andalusian Health Service in patients under 18 years old with type 1 diabetes mellitus (DM1) in our hospital area.Material and Methods: A descriptive observational and retrospective study that includes patients with DM1 under 18 years old from the southern hospital area of...

ea0063p974 | Diabetes, Obesity and Metabolism 3 | ECE2019

Canagliflozin: Ankle-Brachial index (ABPI) and risk of amputations

Laguna Ma del Carmen Serrano , Ponce Maria Hayon , Utrero Sara Leon , Perez Luisa Sebastian , Torres Enrique Redondo , Charneco Miguel Quesada , Vela Elena Torres

Objectives: Assess the canagliflozin effect on the ABPI in patients without previous treatment with iSGLT-2 as a possible etiology of tissue hypoperfusion and a risk factor for amputations.Material and methods: Prospective observational study where we analyzed patients diagnosed of type 2 diabetes mellitus (DM2) with poor metabolic control and without prior treatment with iSGLT-2, which is initiated treatment with canagliflozin. Clinical, biochemical par...

ea0049ep581 | Diabetes therapy | ECE2017

The role of sodium-glucose co-transporter 2 inhibitors as add-on therapy in type 2 diabetes

Ponce Maria Hayon , Blanquez Martinez David , Jimenez Maria Jose Jimenez , Cordova Rossana Sofia Manzanares , Laguna Maria del Carmen Serrano , Charneco Miguel Quesada , Casares Martin Lopez de la Torre

Objective: SGLT2 inhibitors, have been shown to improve glycaemic control, stabilize insulin dosing and mitigate insulin-associated weight gain in patients whose type 2 diabetes mellitus (T2DM) was inadequately controlled. The objective is to evaluate the real-world efficacy and safety of adding iSGLT-2 therapy in inadequately controlled patients with oral antidiabetic drugs and with or without insulin therapy.Materials and methods: This observational st...